Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price9.82 USD
Fair value15.50
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation9.82+0.0% to today ✓
2026-09-19Read Markdown9.27+5.9% to today
2026-07-02Read Accumulation6.80+44.4% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Absci Corporation holds its Markup at $9.82. Consolidating, no directional conviction, held for 32 days.
As held on the ledger · 2026-09-21
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 32 days
Price at the screen
$9.82
Valuation
N/A trailing · -13.73 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.44
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.45%
Below 33%
Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
57.45%
Below 33%
Interest-bearing cash and securities are 57.5% of assets, above the one-third limit.
Fail
Receivables
9.26%
Below 49%
Money owed to the company is 9.3% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Absci's business is fine, but its cash and interest-bearing securities are about 57% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-03. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 57.8% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +58% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech dreams meet collapsing revenue reality
Every new antibody therapy starts with a scientist in a lab hoping one molecule will tame disease where others failed. Absci is chasing that bet across inflammatory conditions, yet its revenue has fallen 82% while it posts zero profit margins and a negative 64% return on equity. The market prices the shares well below our calculated fair value, but the business shows none of the durable traits that justify stepping in.
Analyst notes highlight a strong buy chorus and a $13 target, and the name clears our ethical screen without flags. Still, a forward price to earnings ratio of negative 13 times and an unknown competitive moat leave the story resting on future clinical wins that remain unproven. We see no reason to override those numbers.
Clinical development carries binary trial outcomes and repeated cash calls that can wipe out early gains in months. Currency and sector swings add further volatility to an already fragile setup. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ABSI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Accumulation · changed$9.82+5.9%Entry 8
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
2026-09-19Markdown · changed$9.27-2.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
2026-08-20Accumulation$9.46+14.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
2026-07-20Accumulation$8.30+22.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 22.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
2026-07-18Accumulation$6.80+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
2026-07-16Accumulation$6.80+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.
2026-07-03Accumulation$6.80+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$6.80Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
